Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
NA Selpercatinib Retevmo 40mg, 80mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2020 In Use
NA Selumetinib Koselugo 10mg, 25mg Chemotherapy MEK Inhibitor MEK 1/2 Yes 2020 In Use
C9070 Tafasitamab-cxix Monjuvi 2mg Immunotherapy Monoclonal Antibody CD19 2020 Jan 1, 2021 Apr 1, 2021 No Longer Used
J9349 Tafasitamab-cxix MONJUVI 2mg Immunotherapy Monoclonal Antibody CD19 No 2020 Apr 1, 2021 In Use
J9144 Daratumumab, hyaluronidase-fihj Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Jan 1, 2021 In Use
C9062 Daratumumab Hyaluronidase Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 Jan 1, 2021 No Longer Used
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
NA Cedazuridine and Decitabine Inqovi 100mg, 35mg Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Yes 2020 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
Q5116 Trastuzumab-qyyp Trazimera 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Oct 1, 2019 In Use
Q2053 Brexucabtagene autoleucel Tecartus 2000000 Immunotherapy CAR-T CD-19 No 2020 Apr 1, 2021 In Use
C9073 Brexucabtagene autileucel Tecartus 2000000 Immunotherapy CAR-T CD19 No 2020 Jan 1, 2021 Apr 1, 2021 In Use
NA Tucatinib Tukysa 50mg,150mg Chemotherapy Tyrosine Kinase Inhibitor HER2 Yes 2020 In Use
C9069 Belantamab mafodotin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Jan 1, 2021 No Longer Used
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 In Use
NA Avapritinib Ayvakit 50mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 25mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 200mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Avapritinib Ayvakit 300mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
J9247 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Sep 27, 2021 In Use
Q5112 Trastuzumab-dttb Ontruzant 10mg Immunotherapy Monoclonal Antibody HER2 No 2021 Jul 1, 2019 In Use
C9080 Melphalan flufenamide Pepaxto 1mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2021 Jul 23, 2021 Sep 27, 2021 No Longer Used
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.